Results 91 to 100 of about 29,799 (243)

Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma

, 2016
Approximately 45% of patients with asthma in the United Kingdom are receiving step 3 or higher therapy,1 most commonly inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs).
Lipworth, Brian, Jabbal, Sunny, Anderson, William, Lipworth, Joseph, Manoharan, Arvind   +4 more
core   +1 more source

Social organization and habitat use shape the gut microbiome of a marine fish

Journal of Animal Ecology, EarlyView.
This study provides the first evidence linking habitat use—and to a lesser extent social organization—to gut microbiome composition in a wild marine fish. The results indicate that local habitat conditions are the primary driver of microbial variation, while social effects are detectable but weak.
Aina Pons, Eneko Aspillaga, Ignacio A. Catalán, Tomeu Viver, Robert Arlinghaus, Martina Martorell‐Barceló, Margarida Barcelo‐Serra, Josep Alós   +7 more
wiley   +1 more source

Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer’s disease by administration through an intranasal route

Communications Biology
Bambuterol is a long-acting anti-asthmatic prodrug which releases terbutaline. Terbutaline is an agonist of the β2-adrenergic receptors which is formed by decarbamoylation of bambuterol by butyrylcholinesterase.
Anne-Claire Groo, Thomas Curel, Aurélie Malzert-Fréon, Line Séguy, Ophélie Bento, Sophie Corvaisier, Thomas Culerier, Romain Legrand, Noëlle Callizot, Alexandre Henriques, Georgia Culley, Sylvie Claeysen, Christophe Rochais, Patrick Dallemagne   +13 more
doaj   +1 more source

The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study

International Journal of COPD, 2021
Gema Requena,1 Daniel Dedman,2 Jennifer K Quint,3 Rebecca E Ghosh,2 Rachael Williams,2 Jeanne M Pimenta1 1Respiratory Epidemiology, GSK, Brentford, Middlesex, UK; 2Clinical Practice Research Datalink, MHRA, London, UK; 3National Heart and Lung Institute,
Requena G, Dedman D, Quint JK, Ghosh RE, Williams R, Pimenta JM   +5 more
doaj  

Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study

BMC Pulmonary Medicine, 2018
Background Patients with symptoms of both asthma and chronic obstructive pulmonary disease (COPD) may be classified with the term asthma-COPD overlap (ACO).
Sumitra Shantakumar, Raoh-Fang Pwu, Liesel D’Silva, Keele Wurst, Yao-Wen Kuo, Yen-Yun Yang, Yi-Chen Juan, K. Arnold Chan   +7 more
doaj   +1 more source

Optimal follow-up period after switching to another inhaled corticosteroid/long-acting β2 agonist in patients with asthma: A retrospective study using Japanese administrative claims data. [PDF]

PLoS One, 2022
Kondo R, Maeda S, Kikuchi A, Kiyono H, Sato T.   +4 more
europepmc   +1 more source

Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma

, 2011
Asthma patients who continue to experience symptoms despite being on regular inhaled corticosteroids (ICS) represent a management challenge. Long-acting beta2-agonists (LABA) or anti-leukotrienes (LTRA) are two treatment options that could be considered ...
Christopher J Cates, Lasserson, TJ, Francine M Ducharme, Toby J Lasserson, Ducharme, FM, Cates, CJ   +5 more
core   +1 more source

Decarbonising Respiratory Care: The Impact of a Low‐Carbon Salbutamol Pressurised Metered‐Dose Inhalers

Allergy, EarlyView.
Healthcare systems contribute up to 5% of global GHG emissions, with inhalers contributing a proportion of these. The carbon footprint of current salbutamol inhalers (pMDI with HFA‐134a propellant and DPI) and a planned salbutamol pMDI with low‐GWP propellant HFA‐152a was quantified across seven countries.
James King, Ashley Woodcock, Antonio Anzueto, Alexander J. K. Wilkinson, Christer Janson, Richard Henderson, Sourabh Fulmali, Maximilian Plank   +7 more
wiley   +1 more source

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD

International Journal of COPD, 2018
Colin Reisner,1,2 James Pearle,3 Edward M Kerwin,4 Earl St Rose,1 Patrick Darken1 1Pearl – a member of the AstraZeneca Group, Morristown, NJ, USA; 2AstraZeneca, Gaithersburg, MD, USA; 3California Research Medical Group, Inc., Fullerton, CA, USA ...
Reisner C, Pearle J, Kerwin EM, St Rose E, Darken P   +4 more
doaj  

Successful treatment with inhaled corticosteroid/long-acting β₂-agonist in a case of allergic bronchopulmonary mycosis caused by Schizophyllumcommune. [PDF]

Respir Med Case Rep, 2023
Sekiya M, Sakamoto S, Sekiguchi R, Sadamoto S, Sasaki M, Kamei K, Shibuya K, Kishi K.   +7 more
europepmc   +1 more source